On May 9, 2022, China National Medical Products Administration (NMPA) released the revised draft of the Provisions for Implementation of the Drug Administration Law for public comments.
The Regulations was first issued with immediate effect in 2002, and was later revised in 2019. Compared to the 2019 version, the draft of the 2022 version includes 101 more articles to conform to the pharmaceutical policy reforms in the recent years and the Drug Administration Law revised in 2019. The new contents involve marketing authorization holder system, patent protection, and pharmacovigilance.